University Hospital Galway (UHG) achieved a significant milestone in cardiac care last October by becoming the first hospital in Ireland and the UK to implant the Avalus Ultra biological aortic valve, a major advancement in the field of valvular heart surgery.

The groundbreaking procedure was first performed on Noel O’Brien from County Galway, marking the hospital’s inaugural use of the innovative valve. In a remarkable development, Noel’s brother, Michael, underwent the same life-changing procedure in recent weeks, becoming the eighth patient to receive the implant. Both surgeries were successfully carried out by Professor Alan Soo and his team at UHG.

Both Noel and Michael had experienced symptoms commonly associated with aortic valve disease, a condition where the valve narrows or leaks, forcing the heart to work harder to pump blood. If untreated, the condition can lead to heart failure and other serious complications. Patients with aortic valve disease, either stenosis (blocked) or regurgitant (leaky), often require valve replacement.

The Avalus Ultra valve is a next-generation aortic valve replacement that offers improved durability, enhanced surgical handling, and easier placement. Its introduction places UHG at the forefront of cardiac surgical innovation in Ireland.

Professor Alan Soo, Consultant Cardiothoracic Surgeon, explained that “the introduction of the Avalus Ultra valve represents a new chapter in heart valve surgery. We are proud to lead the way in offering our patients the very latest in cardiac technology, ensuring better outcomes and improved quality of life.”

The successful adoption of this advanced valve system underscores UHG’s commitment to pioneering treatments and delivering world-class cardiac care to patients across Ireland.